Abstract：
BACKGROUND: Cerebral vasculitides are often devastating conditions that require immediate diagnosis and treatment.
METHODS: We report a pathologically proven clinical case of primary central nervous system vasculitis in a 50-year-old man with a diagnosis of relapsing-remitting multiple sclerosis after alemtuzumab therapy, which required additional immunosuppression to control this life-threatening condition.
CONCLUSIONS: In patients presenting subacute neurological deterioration after alemtuzumab therapy, primary central nervous system vasculitis should be considered as a differential diagnosis among other autoimmune conditions.
METHODS: We report a pathologically proven clinical case of primary central nervous system vasculitis in a 50-year-old man with a diagnosis of relapsing-remitting multiple sclerosis after alemtuzumab therapy, which required additional immunosuppression to control this life-threatening condition.
CONCLUSIONS: In patients presenting subacute neurological deterioration after alemtuzumab therapy, primary central nervous system vasculitis should be considered as a differential diagnosis among other autoimmune conditions.
摘要：
背景：脑血管炎通常是破坏性的疾病，需要立即诊断和治疗。
方法：我们报告了一例50岁男性经病理证实的原发性中枢神经系统血管炎的临床病例，在阿仑珠单抗治疗后诊断为复发缓解型多发性硬化，这需要额外的免疫抑制来控制这种危及生命的状况。
结论：阿仑珠单抗治疗后出现亚急性神经恶化的患者，原发性中枢神经系统血管炎应作为其他自身免疫性疾病的鉴别诊断。
方法：我们报告了一例50岁男性经病理证实的原发性中枢神经系统血管炎的临床病例，在阿仑珠单抗治疗后诊断为复发缓解型多发性硬化，这需要额外的免疫抑制来控制这种危及生命的状况。
结论：阿仑珠单抗治疗后出现亚急性神经恶化的患者，原发性中枢神经系统血管炎应作为其他自身免疫性疾病的鉴别诊断。
